REGENEREX PHARMA, INC.: 10-Q filed 2013-10-02
What REGENEREX PHARMA, INC. reported in its quarterly report filed 2013-10-02 (fiscal Q3 2013): 14 published measures, 33 facts as tagged in accession 0001072588-13-000109.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2013-10-02
- Fiscal period
- fiscal Q3 2013
- Accession
- 0001072588-13-000109 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All REGENEREX PHARMA, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-11-30 | 65,441 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-11-30 | -749,656 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-11-30 | 7,780 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-06-01 to 2013-08-31 | -248,303 | USD | 92 |
| 2012-12-01 to 2013-08-31 | -738,192 | USD | 274 |
| 2010-06-26 to 2013-08-31 | -1,636,413 | USD | 1163 |
| 2012-06-01 to 2012-08-31 | -14,421 | USD | 92 |
| 2011-12-01 to 2012-08-31 | -167,023 | USD | 275 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-06-01 to 2013-08-31 | -20,098 | USD | 92 |
| 2012-12-01 to 2013-08-31 | -45,509 | USD | 274 |
| 2010-06-26 to 2013-08-31 | -202,340 | USD | 1163 |
| 2012-06-01 to 2012-08-31 | -28,393 | USD | 92 |
| 2011-12-01 to 2012-08-31 | -52,112 | USD | 275 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-06-01 to 2013-08-31 | 25,000 | USD | 92 |
| 2012-12-01 to 2013-08-31 | 43,000 | USD | 274 |
| 2010-06-26 to 2013-08-31 | 213,408 | USD | 1163 |
| 2012-06-01 to 2012-08-31 | 30,336 | USD | 92 |
| 2011-12-01 to 2012-08-31 | 55,336 | USD | 275 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2010-06-26 to 2013-08-31 | -10,000 | USD | 1163 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-11-30 | -105,837 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-06-01 to 2013-08-31 | 151,107,016 | shares | 92 |
| 2012-12-01 to 2013-08-31 | 150,022,908 | shares | 274 |
| 2012-06-01 to 2012-08-31 | 141,050,802 | shares | 92 |
| 2011-12-01 to 2012-08-31 | 143,334,090 | shares | 275 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-11-30 | 11,274 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-11-30 | 815,097 | USD |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-11-30 | 149,078,000 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-11-30 | 105,324 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-06-01 to 2013-08-31 | 5,419 | USD | 92 |
| 2012-12-01 to 2013-08-31 | 13,963 | USD | 274 |
| 2010-06-26 to 2013-08-31 | 36,638 | USD | 1163 |
| 2012-06-01 to 2012-08-31 | 3,277 | USD | 92 |
| 2011-12-01 to 2012-08-31 | 5,346 | USD | 275 |
Inspect the source
- Entity
- REGENEREX PHARMA, INC. / CIK 0001357878
- Captured
- 2026-09-21T17:18:44.819Z
- SEC response SHA-256
213194c506fa9441e1992f90b01cc25fc346a1dd3e1f77e4d19752e41180a033
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001357878.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))